Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Sunitinib resistance is a significant clinical problem in advanced renal cell carcinoma (RCC).
• Mechanisms of sunitinib resistance require further elucidation for improved therapeutic strategies.
• Identifying novel targets is crucial for overcoming treatment failure in RCC.

Purpose of the Study:

• To identify novel molecular mechanisms underlying sunitinib resistance in RCC.
• To investigate the role of a newly identified long non-coding RNA, lncARSR, in promoting sunitinib resistance.
• To explore therapeutic strategies targeting lncARSR for overcoming sunitinib resistance.

Main Methods:

• Identification and characterization of lncARSR in RCC patient samples.
• In vitro studies using RCC cell lines to assess the function of lncARSR.
• Investigation of the interaction between lncARSR, miR-34/miR-449, and target genes (AXL, c-MET).
• Exosome isolation and analysis to study intercellular transfer of lncARSR.
• In vivo studies evaluating the efficacy of targeting lncARSR or AXL/c-MET.

Main Results:

• A novel lncRNA, lncARSR (lncRNA Activated in RCC with Sunitinib Resistance), was identified and correlated with poor sunitinib response in RCC.
• lncARSR promotes sunitinib resistance by competitively binding miR-34/miR-449, leading to increased AXL and c-MET expression.
• lncARSR is packaged into exosomes and can be transferred to sensitive cells, spreading resistance.
• Targeting lncARSR with locked nucleic acids or inhibiting AXL/c-MET restored sunitinib sensitivity in resistant RCC.

Conclusions:

• lncARSR is a key mediator of sunitinib resistance in advanced RCC.
• lncARSR represents a potential predictive biomarker for sunitinib treatment response.
• Targeting lncARSR or its downstream effectors (AXL/c-MET) offers a promising therapeutic avenue for overcoming sunitinib resistance in RCC.